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Interleukin 2 restores CD3-m chain expression but
fails to generate tumour-specific lytic activity in
tumour-infiltrating lymphocytes derived from human
colorectal hepatic metastases
KF Yoong and DH Adams
Liver Research Laboratories, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK
Summary Metastatic colorectal cancer is usually progressive despite infiltration of the tumours by T lymphocytes, suggesting that these
tumour-infiltrating lymphocytes (TILs) are functionally deficient. Recently, TILs from other tumours have been shown to express reduced
levels of the T-cell receptor signal-transducing CD3-; chain. We were interested to determine whether a similar abnormality existed in TILs
from human colorectal hepatic metastasis (CHM) and, if so, whether correcting the abnormality in vitro would restore anti-tumour activity and
provide support for the development of immunotherapy for colorectal hepatic metastases. Twelve of 19 TILs from colorectal hepatic
metastases were successfully expanded in vitro in high-dose recombinant interleukin 2 (rlL-2) and their specific anti-tumour cytolytic activity
was determined. CD3-positive (CD3+) TILs were HLA-Ddbsh and CD69high, suggesting thatthey had been activated by exposure to antigen but
expressed low levels of CD25, CD71 and the nuclear proliferation antigen Ki-67. Furthermore, they showed reduced expression of CD3-4
compared with autologous peripheral blood T cells (PBTs) and failed to proliferate in the absence of high-dose rlL-2. Expansion of TILs in
rlL-2 resulted in restoration of CD3-t expression and the ability to lyse K562 and Daudi cells but not autologous tumour cells. The absence of
autologous tumour-specific cytolytic T-cell (CTL) activity may be due to the poor immunogenicity of colorectal tumour cells, which we found
expressed only low levels of MHC antigens and CD54 and failed to express MHC II antigens or the co-stimulatory molecules CD80, CD86
or CD106. The inability of rlL-2 to generate tumour-specific CTLs despite restoration of CD3-l expression and the presence of an intact lytic
mechanism suggests that successful immunotherapy may require the development of strategies to increase the immunogenicity of this
tumour.
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T cells are believed to mediate specific anti-tumour responses in
several human cancers, particularly malignant melanoma and
renal cell carcinoma (Schendel et al, 1993; Kawakami et al, 1994;
Robbins and Kawakami, 1996). Tumour-specific cytolytic T cells
(CTLs) can be generated by culturing tumour-infiltrating lympho-
cytes (TILs) and peripheral blood lymphocytes (PBLs) derived
from patients with melanoma in recombinant interleukin 2 (rIL-2)
and other cytokines (Rivoltini et al, 1995). In addition, several
peptide epitopes that serve as recognition structures for
melanoma-derived TILs and PBLs have been identified, thus
providing evidence for the existence of tumour-specific T-cell
responses in melanoma (van der Bruggen et al, 1991; Robbins and
Kawakami, 1996).
Despite the presence of a lymphocytic infiltrate, many human
solid tumours, including colorectal tumours, grow relentlessly,
suggesting that these TILs are functionally suppressed in vivo. In
support ofthis hypothesis, several in vitro studies have shown that
freshly isolated TILs fail to proliferate, secrete cytokines or lyse
tumourcells, and a generalized suppression ofT-cell responses has
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been described in tumour-bearing hosts (Miescher et al, 1986,
1988). The factors responsible for this suppression are not known
but may include the release ofsuppressorcytokines, such as IL-10
and TGF-f, by infiltrating mononuclear cells and tumour cells
(Nakagomi et al, 1995; Barth et al, 1996; Camp et al, 1996). More
recently, it has been reported that TILs derived from experimental
murine tumours (Mizoguchi et al, 1992) and patients with primary
colon (Nakagomi etal, 1993) andrenal cell carcinoma (Finke etal,
1993) show reduced expression ofCD3-4, an important signalling
component of the T-cell receptor (TCR). The phosphorylation of
tyrosine residues on the CD3-4 chain is anearly and critical step in
T-cell activation after antigen recognition by the TCR-CD3
complex (Robey and Allison, 1995). Thus, reduced expression of
CD3-4 on TILs could result in defective T-cell activation after
recognition of tumour antigens and thereby explain why TILs fail
to lyse tumour cells in vivo. However, in addition to signals from
the TCR-CD3 complex, optimal T-cell activation requires a
second, antigen-independent co-stimulatory signal mediated by
accessory pathways, such as CD28/CD80, CD54/CDlla (ICAM-
1/LFA-1), CD49d/CD106 (VLA-4/VCAM-1) and CD2/CD58
(Allison et al, 1995). In the absence ofa co-stimulatory signal, the
interaction between TCR-CD3 and peptide-MHC complexes is
suboptimal and can result in T-cell anergy. Thus, the absence of
appropriate co-stimulatory molecules on tumour cells could also
be responsible forthe incomplete activation and defective function
ofTILs.
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Metastasis to the liver occurs in over 60% of patients with
primary colorectal cancers and is one of the commonest causes of
cancer death in the developed world. The only effective treatment,
surgical resection, is possible in less than 10% of patients, of
whom only 25% are cured. The rest develop recurrent disease
resulting in an overall cure rate of less than 3% (Hughes, 1988;
Baer et al, 1989; Asbun and Hughes, 1993). There is thus an urgent
need to develop a safe and effective treatment for this disease,
hence the resurgence of interest in immunotherapy. Clinical trials
ofadoptive immunotherapy have resulted in objective responses in
a proportion of patients with metastatic melanoma, but the few
studies that have been carried out in colorectal carcinoma have
given disappointing results. The aim of the present study was to
characterize the activation status, proliferative ability and func-
tional activity of T cells in human colorectal hepatic metastasis to
determine whether therapeutic manipulation, either in vitro or in
vivo, was likely to result in effective anti-tumour immunotherapy.
Ourresults show that very few TILs proliferate in situ in colorectal
hepatic metastases and that this lack of proliferation is associated
with reduced CD3-1 expression and an inability to lyse either
autologous tumour cells or NK and LAK cell targets in vitro. After
culture in high-dose rIL-2, intracytoplasmic CD3-1 levels were
restored, and TILs were then able to kill Daudi and K562 targets
but no tumour-specific killing was demonstrated. The inability of
cultured TILs to lyse autologous tumour cells despite restoration
of CD3-; expression after rIL-2 activation implies the involve-
ment of other factors in the failure of anti-tumour responses.
These factors are likely to include a lack of MHC antigens and
co-stimulatory molecules on tumour cells.
MATERIALS AND METHODS
Patients' characteristics
Fresh tumour specimens were obtained from 19 patients (nine
men, ten women) with a median age of 57 years (range 21-79
years) who underwent liver resection for colorectal hepatic metas-
tasis at the Liver Unit, Queen Elizabeth Hospital, Birmingham,
UK. Six tumours were histologically well differentiated, nine
moderately differentiated and four poorly differentiated adeno-
carcinoma. None of the patients was taking immunosuppressive
drugs, corticosteroids or chemotherapy, and none had evidence of
prior liver disease at the time of surgery.
Sample collection
Part of the tumour was removed together with a piece of autolo-
gous non-involved liver tissue, snap frozen in liquid nitrogen and
stored at -70°C until used for subsequent immunohistochemistry.
Another piece of tumour was removed for tumour cell and TIL
isolation, and the rest of the tumour was fixed for routine
histological analysis.
Isolation of TILs and tumour cells
Fresh tumour tissues were placed in sterile medium and processed
immediately as described previously (Shimizu et al, 1990;
Yannelli, 1991). Tumour tissue was cut into small pieces, washed
in phosphate-buffered saline (PBS) to remove contaminating red
blood cells and necrotic debris and digested in RPMI-1640 (Gibco,
Paisley, UK) supplemented with 0.2% (w/v) collagenase type IV
(Sigma, Poole, Dorset, UK) and 10% fetal calf serum (FCS)
(Sigma) for 2-3 h at room temperature with continuous stirring.
The resulting single-cell suspension was filtered through a wire
mesh, washed in PBS and layered onto a double-density gradient
consisting of 75% and 100% Ficoll-Hypaque (Lymphoprep,
Nycomed, Birmingham, UK) and centrifuged at 1600 r.p.m. for
30 min at room temperature. The tumour cell-enriched fraction
was recovered from the supernatant/75% interface and mononu-
clear cells from the 75%/100% interface. The recovered cells were
washed twice with PBS and the cell count and viability determined
by trypan blue exclusion. Some of the tumour cells were used as
target cells for cytotoxicity assays of fresh TILs, the rest were
cryopreserved in RPMI-1640 medium supplemented with 50%
(v/v) FCS and 10% (v/v) dimethyl sulphoxide (DMSO) (Sigma)
for future cytotoxicity assays using rIL-2-expanded TILs. An
aliquot of fresh TIL was cryopreserved in RPMI-1640 with 50%
FCS and 10% DMSO, and the remaining cells were used for cyto-
toxicity assays, flow cytometric analysis and culture in rIL-2.
Isolation of peripheral blood lymphocytes
Heparinized venous blood was collected from ten healthy volun-
teers and from each of the patients immediately before surgery.
Peripheral blood lymphocytes (PBL) were isolated by
Ficoll-Hypaque density gradient centrifugation and washed thor-
oughly in PBS. An aliquot of cells was cryopreserved for future
use and the remaining cells used for flow cytometric analysis,
cytotoxic assays and culture in rIL-2.
Lymphocyte culture
Parallel cultures of TILs and autologous PBLs were initiated at a
concentration of 0.5 x 106 lymphocytes ml-' of tissue culture
medium (RPMI-1640 supplemented with 10% (v/v) FCS, peni-
cillin-streptomycin-amphotericin and 2 mM L-glutamine) supple-
mented with 1000 IU ml-' human rIL-2 (Eurocetus). Cultures were
started in 24-well plates with 1.5-ml aliquots in each well and
incubated at 37°C in a humidified atmosphere with 5% carbon
dioxide. The cell concentration was maintained between 1.0 and
2.0 x 106 ml-' by splitting the cultures and adding fresh medium
every 2-3 days. When cell concentration exceeded 2.0 x 106 ml-',
cultures were transferred to T75 flasks for further expansion.
Monoclonal antibodies (MAbs)
A summary of the monoclonal antibodies and immunoglobulins
used in this study is given in Table 1. All the primary antibodies
were mouse monoclonal of IgGI or IgG2a isotype except for the
rabbit anti-human CD3 (Dako, High Wycombe, UK) used for
double immunostaining in conjunction with anti-Ki-67.
Flow cytometry
Two-colour flow cytometry using anti-CD3 to detect T cells and
the following primary antibodies was carried out on freshly
isolated and rIL-2-expanded TILs and autologous PBLs to study
the expression ofdifferentiation markers (CD3, CD4, CD8, CD14,
CD45RO and CD56), activation markers (CD25, HLA-Dr, CD69
and CD71) and cellular adhesion molecules (CD62L, a4p7,
aIEL,B7, CD1la, CD18, CD29 and CD49d) using established
methods (Adams et al, 1997). The expression of the CD3-1 chain
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Table 1 Mouse anti-human monoclonal antibodies used for flow cytometric
analysis and immunohistochemical studies of colorectal hepatic metastases
Specificity Clone Isotype Source
CD 3 UCHT1 IgGl Dako
CD 4 T4-4D7 IgG2a Unipath
CD 8 DK25 IgGl Dako
CD14 63D3 IgGi Dr S Shaw
CD 22 4KB128 IgGi Dako
CD 56 MOC-1 IgGl Dako
CD 25 ACT-1 IgGl Dako
CD 28 L293 IgGl Becton-Dickinson
CD 45RO UCHL1 lgG2a Dako
HLA-DR CR3/43 IgGl Dako
HLA-ABC W6/32 IgG2a Dako
CD 69 L78 IgGi Becton-Dickinson
CD 71 Ber-T9 IgGl Dako
CD 62L (L-selectin) Leu-8 IgGl Becton-Dickinson
a4P7 ACT-1 IgGl Dr A Lazarowitz
alEL,B7 Ber-ACT8 IgGi Dako
CD 49d (VLA-4-a) HP/1 IgGi Coulter
CD 29 (VLA-4-P) MAb13 IgGi Dr K Yamada
CD 11a (LFA-1-a) R.31 IgGl Dr R Rothlein
CD 18 (LFA-1-,B) R.15/7 IgGl Dr R Rothlein
CD 3-zeta TIA-2 IgGl Coulter
was determined by flow cytometric analysis ofpermeabilized cells
using a MAb specific for the cytoplasmic domain of the 4-chain.
Cells were suspended with a permeabilizing agent (Permeafix,
Ortho, CA, USA) for 40 min at room temperature before labelling
with anti-CD3-1 MAb. Immunofluorescent staining for flow
cytometry was carried out using standard techniques; briefly,
lymphocyte suspensions were incubated with normal human
immunoglobulin to block Fc receptors and 0.5 x 106 cells were
incubated with 5 jil of the optimal concentration (between 10 and
50 jg ml-') primary antibody in 100 jl of FACS medium (PBS
with 0.2% FCS and 0.02% sodium azide), washed twice and then
incubated with fluorescein isothiocyanate (FITC)-conjugated
F(ab)2 fragments of rabbit anti-mouse immunoglobulin (Dako) at
1:20 dilution. Cells were washed twice with FACS medium and
incubated with normal mouse serum to saturate free binding sites
on the FITC-conjugated F(ab)2 fragments. Phycoerythrin-conju-
gated anti-CD3 (Dako) was used as the secondprimary antibody to
detect T cells. All incubations were carried out for 30 min at 4°C.
After the final incubation, cells were washed twice and then fixed
in 1% paraformaldehyde. Two-colour analysis was carried out
using FACS 440 (Becton-Dickinson) with a lymphocyte gate to
exclude dead cells and debris. At least 10 000 cells were analysed
in each sample. Irrelevant mouse isotypes IgG1 and IgG2a were
used as control antibodies.
Immunohistochemistry
Paraffin-embedded tissue sections
In situ proliferation ofTILs was determined by double-staining for
the nuclear proliferation antigen Ki-67 and anti-CD3 using 6-im
paraffin-embedded sections of tumour tissue obtained from ten
patients. Sections were dewaxed with xylene-alcohol and treated
with 3% hydrogen peroxide in methanol for 10 min to block
endogenous peroxidase, followed by microwaving for 30 min in
citric acid (2.1 g 1-' adjusted to pH 6.0 with sodium hydroxide) to
enhance antigen retrieval. For double-staining, mouse anti-human
Ki-67 and rabbit anti-human CD3 primary antibodies were applied
simultaneously to the sections. Anti-Ki-67 was detected by the
indirect peroxidase-antiperoxidase technique and developed using
diaminobenzidine tetrahydrochloride. The indirect alkaline phos-
phatase-antialkaline phosphatase (APAAP) method was used to
detect anti-CD3, and the resulting enzyme complexes were devel-
oped with naphthol AS-MX (Sigma, Poole, Dorset, UK) and Fast
Red TR substrate (Sigma). The sections were counterstained with
Mayer's haematoxylin. Normal sheep serum applied in place of
anti-Ki-67 or anti-CD3 was used as negative control. Tonsillar
sections stained with only anti-Ki-67 or anti-CD3 were used as
positive controls. Approximately 500 CD3 + cells were counted on
each section at magnification x 160 to determine the percentage of
cells that were doubly positive for anti-CD3 and -Ki-67.
Frozen-tissue sections
The surface expression of CD80 (B-7.1) and CD86 (B-7.2) on
cells was assessed immunohistochemically and by their ability to
bind a CTLA-4-Ig fusion protein (Sayegh et al, 1995) (a gift from
P Linsley) in ten cases ofcolorectal hepatic metastasis. In addition,
the expression of CD28 on infiltrating mononuclear cells was
determined by standard indirect immunostaining with mouse anti-
human CD28 detected by rabbit anti-mouse Ig and developed by
APAAP and the Fast Red technique (Adams et al, 1996). Cryostat
sections (6 jim) were fixed in acetone for 10 min and then incu-
bated with CTLA-4-Ig, followed by abiotinylated goat antibody to
the human Igy chain (Dako) detected using an alkaline phos-
phatase conjugated streptavidin complex developed with naph-
thol-AX and Fast Red TR. Sections were counterstained with
haematoxylin. All incubations were carried out at room tempera-
ture for 45 min and sections were washed for 5 min with two
changes of buffer in between incubations. Negative control
sections were stained with an irrelevant mouse monoclonal anti-
body. A semiquantitative assessment ofthe proportion ofcells that
showed immunoreactivity was carried out on individual sections
as follows: 0, none; 1-10%, few; 11-50%, some; > 50%, most of
the cells were positive for a given antigenic determinant.
Cytotoxicity assays
Fresh and rIL-2-expanded TILs and PBLs were assessed, after
various times in culture, for cytotoxic activity against the
following tumour cell targets: (1) K562, a human erythro-
leukaemia cell line that is sensitive to lysis by NK cells; (2) Daudi,
a Burkitt's lymphoma cell line, which is LAK cell sensitive;
(3) allogeneic tumour cells; and (4) autologous tumour cells.
Cytotoxic activity was assessed by a standard 4-h 5'Chromium
release assay-using 5 x 103 target cells per well. Approximately
1 x 106 target cells were incubated with 100 ,uCi of 51Cr for 1 h at
37°C in humidified air with 5% carbon dioxide and then washed
twice with PBS. Target and effector cells were suspended in
RPMI-1640 with 10% FCS. Then, 100 jil aliquots of effector cell
and target cell suspensions were added in a final volume of200 jil
to each well of a 96-well round-bottom plate. MHC class I
restricted lysis was assessed by incubating 106 tumour targets with
2 jig of anti-HLA-ABC MAb (W6/32, Dako) during the period of
chromium labelling. All determinations were carried out in tripli-
cate with effector-target ratios ranging from 5:1 to 40:1. The
plates were centrifuged at 50g for 5 min and incubated at 37°C in
humidified air with 5% carbon dioxide for 4 h. After incubation,
the plates were centrifuged at 250g for 5 min and 100 ,ul ofsuper-
natant from each well removed for measurement of released
British Journal of Cancer(1998) 77(7), 1072-1081 0 CancerResearch Campa.qn 1998Lymphocytes from human colorectalhepatic metastases 1075
radioactivity, expressed as counts per min (c.p.m.), using a y-
counter. The percentage of specific lysis oftarget cells by effector
cells was calculated according to the formula as follows:
Specific lysis (%) = Experimental release - spontaneous release
Maximal release - spontaneous release x 100
Spontaneous release and maximal release of radioactivity were
determined by incubating target cells with medium and 1% Triton
X-100, respectively, in control wells. Spontaneous release from
K562 and Daudi targets was always less than 10% of maximal
release. Cryopreserved autologous and allogeneic tumour cells
were thawed in medium containing 20% FCS, washed twice,
checked for viability and radiolabelled before being used as fresh
tumour targets. Tumour cells with less than 70% viability as deter-
mined by trypan exclusion dye were not used as targets in cyto-
toxicity assays. Consistent with the findings ofother investigators,
spontaneous release from fresh tumour targets was high but always
less than 25% ofmaximal release (Sanderson, 1976).
Statistical analysis
Results of positive cell enumeration in FACS analysis were
expressed as mean ± s.e.m. Other values were given as median
with range in brackets. Differences between independent groups
were analysed using the Mann-Whitney U-test and differences
between studies of the same group using Wilcoxon matched-pairs
test. The level ofsignificance was set at P < 0.05.
RESULTS
TILs and tumour cells were successfully isolated from
tumour tissue
TILs were isolated from 19 tumours; the median weight oftumour
processed was 11.3 g (range 4.5-35.2 g) and the median number of
TILs recovered was 2.1 x 106 g-I (range 0.5-10.4 x 106 g-1). The
median viability of tumour cells was 80% (0-94%) and that of
TILs greater than 95% in all cases.
T cells infiltrating hepatic colorectal tumours show low
levels of proliferation in situ
The most intense CD3+ T-cell infiltration was found in the liver
tissue surrounding the tumour, and very few T-cells were seen in
direct contact with tumour cells (Figure 1). Double-immunos-
taining of paraffin-embedded tumour sections with antibodies to
CD3 and the nuclear proliferation antigen Ki-67 showed that very
few of the infiltrating lymphocytes were in active cell cycle
because less than 10% of the CD3+ TILs were positive for Ki-67
(Figure 1). Quantitative assessment of the histological sections
revealed that a median 1.7% (range 1.0-3.9%) of the CD3+ cells
were positive for Ki-67. In contrast, numerous tumour cells
(median 35%, range 17.0-51%) showed immunoreactivity for
anti-Ki-67 (Figure 1).
The majority of TILs from colorectal hepatic metastases
are activated memory T cells (Figures 2 and 3)
Lymphocytes infiltrating colorectal hepatic metastasis comprised
mainly CD3+ T cells (n = 16, 74 ± 4%) with a small population of
CD56+ cells (n = 16, 17 ± 2%). Approximately halfofthe CD56+
B
Figure 1 Micrographs showing double-immunostaining of colorectal hepatic
metastasis with anti-CD3 (red) and anti-Ki-67 (dark brown). Very few CD3+
cells were positive for Ki-67; in contrast, numerous tumour cells showed
immunoreactivity for Ki-67 (arrows). Intense infiltrates of CD3 + cells were
detected in the peritumoral margin (A) and tumour edge (B), although few
were in direct contact with tumour cells (N, normal adjacent liver; T, tumour).
Fewer CD3+ cells were detected more centrally in the tumour
(C). Magnification x 150
cells were also positive for CD3. All the TIL populations were
enriched in CD4+ T cells and this was reflected by a high
CD4/CD8 ratio (mean 2.3 ± 0.3). A higher percentage of CD14+
cells was seen in TILs (n = 16, 23 ± 4%) than in PBLs (n = 15, 7 ±
2%, P < 0.001). Fewer than 5% of the TIL population expressed
the B-cell marker CD22. There were significantly more
CD3+/CD45RO+ memory T cells in TILs (93 ± 4%) than is autol-
ogous peripheral blood T cells (PBT) (53 ± 3%, P < 0.001) and a
higher percentage of TILs were L-selectinbow CD1 la/CD18high and
CD29/CD49dhigh, consistent with a memory cell phenotype
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Figure 2 Two-colour flow cytometric analysis showing percentage
(mean ± s.e.m.) of CD3+ cells in fresh TILs and PBTs expressing CD45RO
and activation markers. A significantly higher proportion of T cells expressed
CD45RO, HLA-DR, CD69 and CD25 compared with autologous PBTs
(P< 0.001). *, TILs; l, PBLs
(Figures 2 and 3). More CD3+ TILs expressed the activation
markers CD69 (74 ± 4%), CD25 (18 ± 2%) and HLA-DR (62 ±
6%) than did PBTs (12 ± 6%, 11 ± 2% and 21 ± 3% respectively, P
< 0.001). There was no significant difference in the low numbers
of TILs and PBTs that expressed CD71 (the transferrin receptor)
(Figure 2). No significant difference was observed for the expres-
sion of a407 between TILs and PBLs. However, a small but
significant subset of CD3+ TILs was positive for aIEL,B7 (14 +
2%) compared with PBTs (2± 0.3%, P < 0.001) (Figure 3).
TILs and autologous PBLs can be expanded by culture
in high-dose rIL-2
In the presence of 1000 IU ml-' rIL-2, 12 of 19 (63%) TILs prolif-
erated after a median lag phase of8 days (range 3-18 days). Ten of
19 (53%) autologous PBLs also proliferated in response to exoge-
nous rIL-2, and in all of these cases the corresponding TILs had
also responded to rIL-2. A wide range in the extent and duration of
cell expansion was observed for both TILs and PBLs. The median
expansion fold for TILs in culture was 134 (41-4000) after a
median duration of 35 days (16-63 days) and for PBLs was 65
(20-150) after a median duration of28 days (9-46 days).
Tumour cells in colorectal hepatic metastases express
low levels of MHC antigens and co-stimulatory
molecules
Immunohistochemistry showed that tumour cells in colorectal
hepatic metastasis do not express CD28 ligands. The tumours were
negative for CD80 (B-7.1) and failed to bind CTLA-4-Ig,
suggesting that they do not express altemative CD28 ligands. In
contrast, the majority of mononuclear cells infiltrating CHM
express the CD28 and CD80 receptors. MHC antigens were
confined to inflammatory cells; tumour cells were negative for
MHCI and MHCII
Fresh TILs have impaired cytotoxic effector function
associated with reduced CD3-1 chain expression
Freshly isolated TILs (n = 9) were not able to lyse K562, Daudi or
autologous tumour cell targets (Figure 4). In contrast, PBLs
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Figure 3 Expression of cell adhesion molecules on fresh TILs and PBLs.
Very few CD3+ fresh TILs expressed CD62L (L-selection) compared with
PBTs (P< 0.001). In contrast, a small but significant subset of CD3+ fresh
TILs were positive for MLA (alEL,B7) (P< 0.001). A significantly higher
percentage of CD3+ TILs expressed CD29 (P< 0.001) compared with PBTs.
Almost all the CD3+ cells in both TILs and PBTs were positive for CD18. Data
represent mean ± s.e.m.% positive cells (ACT-1, a4,7). *, TlLs; O, PBLs
freshly isolated from tumour-bearing patients (n = 9) showed
intact spontaneous NK activity by lysing K562 targets to similar
extent as PBLs derived from healthy volunteers (n = 10). Fresh
PBLs from cancer patients or from healthy volunteers failed to
lyse Daudi or autologous tumour targets (data not shown).
The expression of the CD3-1 chain in T cells from freshly
isolated TILs and autologous PBLs was compared with that in T
cells from healthy controls using two-colour flow cytometry
(Figure 7). The results are expressed as median channel fluores-
cence (MCF) of the test sample -MCF of an isotype-matched
control MAb. Fresh TILs from colorectal hepatic metastases had
significantly lower expression of CD3-1 chain (n = 10, MCF
56 ± 3) in comparison to autologous PBTs (n = 12, MCF77 + 4,
P<0.01) andhealthy control PBTs (n = 10, MCF 83 ± 2, P<0.001).
Although autologous PBTs expressed less 4-chain compared with
healthy controls' PBTs, the difference did not reach statistical
significance. The expression of CD3-E was also studied in the
same group ofpatients and healthy controls to determine whether
its expression was associated with the decrease in 4-expression.
There was no significant difference in the expression of CD3-E in
fresh TILs (n = 11, MCF 92 ± 4) compared with fresh PBTs from
cancerpatients (n = 11, MCF 105 ± 6) andhealthy control subjects
(n = 10, MCF 97±4), suggesting that the reduced levels ofCD3-4
chain were not due to reduced levels ofthe TCR per se (Figure 8).
Long-term culture of TILs results in a predominance of
CD3 + T cells
The phenotype of TILs in culture was monitored serially using
two-colour flow cytometry. After 2 weeks of culture, the
percentage ofCD3+ T cells varied between 60% and 95%, but this
proportion increased with time and was always greater than 95%
after 4 weeks of culture. All the early TIL cultures were enriched
in CD4+ T cells, but three cultures became CD8+ enriched in the
later stages. The percentage of CD56+ cells increased in early
cultures and accounted for 28 ± 4% of TIL populations, however
this proportion decreased with increasing duration of culture. The
expression of L-selectin (58 ± 6%) and a407 (83 ± 4%) on
CD3+ T cells was up-regulated in the early stages of culture but
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Figure 4 A comparison of cytolytic activities of fresh TILs (n = 9),
autologous PBLs (n = 9) and healthy controls' PBLs (n = 10) against K562
tumour targets assessed by 4-h chromium release assay. Data represent
mean ± s.e.m. percentage specific lysis. E/T, effector-target ratio
declined later. Cultured TILs and PBTs showed higher expression
of both the a (92 ± 4%)- and (90 ± 4%)-chains of VLA-4 in
comparison with freshly isolated cells (P < 0.01). CD3+ T cells in
TIL cultures showed higher expression of HLA-Dr (92 ± 2%),
CD25 (45 ± 7%) and CD71 (53 ± 7%) compared with fresh TILs
(P < 0.01). However, CD69 was down-regulated, with only
39 ± 3% of CD3+ cells in TIL cultures expressing this early
activation molecule.
Culture in rlL-2 reverses the functional defect and
restores CD3-; chain expression in TILs (Figure 7)
When the expression of the CD3-4 chain was determined in TILs
and autologous PBTs after 4-6 weeks of culture in 1000 IU rIL-2
ml-', the levels ofCD3-; were restored to those seen in PBTs from
healthy controls: (1) cultured TIL CD3-; chain expression (n = 8)
MCF 82 ± 3 compared with uncultured/fresh TILs (n = 10) MCF
56 ± 3 (P < 0.01) and (2) CD3-t chain expression in cultured PBTs
from cancer patients (n = 8) MCF 84 ± 3 compared with uncul-
tured/fresh PBTs from cancer patients (n = 12) MCF 77 ± 4 and
PBTs from healthy controls (n = 10) MCF 83 ±2.
Parallel cultures ofTILs (n = 12) and autologous PBLs (n = 10)
were set up to allow us to monitor cytoxicity against K562, Daudi,
allogeneic and autologous tumour cell targets serially in cells that
had been cultured under identical conditions (Figures 5A and B).
After activation in rlL-2, the majority ofTILs (11 out of 12) and all
PBLs (ten out often) cultures acquired the ability to lyse K562 and
Daudi targets (significant cytotoxicity defined as specific lysis of
greater than 20% at 40:1 effector-target ratio). The highest cyto-
toxicity against K562 and Daudi targets was detected in the first 30
days ofculture, and this usually corresponded to a high proportion
of CD56+ cells at this stage of culture. The major histocompati-
bility complex (MHC)-unrestricted cytotoxicity ofboth LAK cell-
sensitive Daudi and NK cell-sensitive K562 tumour targets
diminished with time, and this was associated with a decrease in
the number ofCD56+ cells in TIL and PBL cultures.
Significant levels of autologous tumour cytotoxicity were
detected in 4 out of 12 TIL cultures associated with high levels of
LAK cell activity. The phenotypic and cytotoxicity profiles of
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Figure 5 Cytolytic activities of IL-2-cultured TILs (A) and PBLs (B) after
10-20 days of culture against a panel of different tumour targets assessed by
4-h chromium release assay. Both TILs and PBLs showed significantly higher
non-MHC-restricted lysis of K562 and Daudi targets than autologous and
allogeneic targets. Data represent mean ± s.e.m.% specific lysis for 12 TIL
and ten PBL cultures
these autologous tumour-reactive TIL cultures are shown in Table
2. The ability to lyse autologous tumour targets decreased rapidly
with time and was not detectable in cultures more than 40 days old.
In contrast, significant levels of autologous tumour cytotoxicity
were not detected in any ofthe PBL cultures despite their ability to
lyse K562 and Daudi targets. Three of the four TIL cultures that
showed autologous tumour cytotoxicity were further examined for
the presence of MHC class I restricted lysis of autologous tumour
cells (Figure 6). The preincubation of both allogeneic and autolo-
gous tumour cells with anti-MHC class I blocking antibodies
did not result in decreased cytotoxicity of tumour cells by the
autologous tumour-reactive TILs.
DISCUSSION
Adoptive immunotherapy, using autologous TILs expanded in
vitro in IL-2, has resulted in objective responses in a proportion of
patients with metastatic melanoma (Rosenberg et al, 1994).
However, initial studies in colorectal cancer were disappointing
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Figure 8 Flow cytometric analysis comparing the median channel
fluorescence of CD3-c expression on fresh TILs (n = 10), PBTs (n = 12) and
control PBTs (n = 10). Differences in median channel fluorescence intensities
between fresh TILs, PBTs and control PBTs are not statistically significant
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Figure 7 Two-colour flow cytometric analysis comparing CD3-; expression
on CD3 + T cells in fresh TILs (n = 10) and PBTs (n = 12), after 4-6 weeks of
culture in IL-2 and healthy controls' PBTs (n = 10). Horizontal bars represent
median value of the difference between median channel fluorescence of test
sample and that of the isotype-matched control MAb (TIL vs PBT, P < 0.001;
TIL vs control PBT, P < 0.001; TIL vs IL-2 TIL, P < 0.01)
and it is unclear whether T cells play an important role in host
defence against this cancer (Miescher et al, 1986). Despite
provoking a lymphocytic infiltrate, colorectal cancer is a
relentlessly progressive disease, suggesting that immune responses
to the tumour are suppressed in vivo. In order to determine
whether immunotherapy is a realistic option for metastatic
colorectal cancer, we investigated the mechanisms behind this
immune suppression and tried to develop cytolytic effector cells in
vitro from lymphocytes isolated from human colorectal hepatic
metastases. In the present paper, we show that T cells infiltrating
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colorectal hepatic metastases have depressed levels of the CD-34
chain and are functionally suppressed in vitro. Although we were
able to restore CD-34 levels and generate lytic activity against
tumour cell lines in vitro by culturing TILs in high-dose IL-2, we
were unable to establish tumour-specific cytolytic activity. This is
likely to be a consequence of the low levels of MHC antigens and
co-stimulatory molecules expressed by colorectal metastases.
Thus, more sophisticated strategies to increase the immuno-
genicity of this tumour may be required to stimulate an effective
T-cell response.
Although we observed large numbers of CD45RO+ memory
T cells in human colorectal hepatic metastasis, most of these cells
were found in the tumour stroma and in the non-involved liver
adjacent to the tumour rather than within the tumour itself.
Furthermore, these TILs were arrested in a partly activated but
non-proliferative state as demonstrated by their failure to express
Ki-67, a nuclear proliferation antigen that is expressed by cells in
all phases of the cell cycle except Go (Campana et al, 1988). The
TILs were, however, CD69 and HLA-Dr positive, suggesting prior
activation by antigen, although very few TILs expressed either
interleukin 2 or transferrin receptors, both of which are up-regu-
lated on actively proliferating T cells (Kronke et al, 1985). The
lack of CD71 expression is consistent with the findings of Kudoh
et al (1994) who reported reduced CD71 expression and poor in
vitro proliferative responses to IL-2 and CD3 cross-linking in TILs
from renal cell carcinoma. In our study, the lack of Ki-67 expres-
sion in vivo was associated with a failure of freshly isolated TILs
to lyse tumour targets in vitro. In contrast, freshly isolated autolo-
gous PBLs were able to lyse K562 targets normally, suggesting
that TILs are suppressed locally within the tumour.
The functional impairment of anti-tumour lymphocyte
responses may be important for progressive tumour growth in
metastatic colorectal cancer. In addition to the local suppression of
T cells within the tumour, more general and systemic defects in
cell-mediated immunity have been described in cancer patients,
including those with colorectal cancer (Nakagomi et al, 1993;
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Table 2 Cytotoxicity and phenotypic profiles of four autologous tumour-reactive TIL cultures at various time points of culture in rlL-2
Specific Iysis of tumour targets at 40:1 effector-target ratio (%) Phenotypic composition (% positive cells)
TIL Days of culture Daudi K562 Autologous Allogeneic CD3 CD4 CD8 CD56
4 10-20 5 47 ND ND 97 45 48 8
21-30 13 46 33 26 100 30 58 4
31-40 14 22 17 13 ND ND ND ND
>40 4 14 ND ND 99 25 66 2
6 10-20 51 50 20 17 86 54 46 49
21-30 66 65 10 25 87 65 24 26
31-40 5 28 ND ND 97 89 32 12
> 40 8 24 ND ND 91 87 46 10
7 10-20 47 49 27 20 76 50 43 39
21-30 21 64 6 31 72 49 54 44
31-40 14 30 0 0 95 24 69 20
> 40 7 20 ND ND 98 39 77 ND
8 10-20 27 61 21 0 96 75 34 17
21-30 19 40 0 0 100 97 14 6
31-40 0 1 ND ND 99 97 11 4
> 40 ND ND ND ND ND ND ND ND
Bateman et al, 1995; Coventry et al, 1996). The mechanism under-
lying the immune suppression of the tumour-bearing host is not
fully understood but may involve structural defects in the
TCR-CD3 complex and its associated signal transduction path-
ways (Mizoguchi et al, 1992; Finke et al, 1993; Nakagomi et al,
1993). In the present study, we found that the functionally defi-
cient T cells derived from colorectal hepatic metastases had signif-
icantly reduced expression of the CD3-1 chain compared with
autologous circulating T cells isolated at the same time. This was
not due to reduced expression of CD3/TCR per se because CD3
expression as determined by UCHT-I binding and levels ofCD3-E
chain were maintained. The fact that T cells isolated from periph-
eral blood of the cancer patients in our study expressed normal
levels of CD3-4 and had an intact lytic mechanism is interesting
and suggests that the T-cell defect is largely confined to TILs and
spares circulating T cells. This is in contrast to some animal and
human studies showing reduced CD3-; chain expression in circu-
lating T cells from tumour-bearing hosts (Mizoguchi et al, 1992;
Nakagomi et al, 1993). The consequences ofreduced CD3-t chain
levels are likely to be functionally important because phosphoryla-
tion of immunoreceptor tyrosine-based activation motifs on the
intracytoplasmic component of the CD3-; chain by protein tyro-
sine kinases (including p561ck) is an important early event in T-cell
activation after TCR-CD3 engagement (Robey and Allison,
1995). Reduced levels ofCD3-; result in arelative lack oftyrosine
residues for phosphorylation and reduced recruitment and phos-
phorylation of downstream signal-transducing molecules, such as
ZAP-70, leading to a failure of IL-2 secretion and IL-2 receptor
expression and ineffective T-cell activation. Thus, a relative lack
of CD3-; could explain the low proliferative activity and lack of
CD25 and CD71 expression in T cells infiltrating colorectal
hepatic metastases. A similar mechanism may also apply to TILs
from primary breast and renal tumours in which reduced IL-2
production and CD25 expression have been reported (Maeurer et
al, 1995; Nakagomi et al, 1995; Coventry et al, 1996).
In most ofthe TILs preparations, we were able to overcome the
proliferative block by culturing in high-dose rIL-2, which also
restored levels of CD3-; to those seen in healthy controls.
Furthermore, these TIL preparations acquired the ability to lyse
the non-MHC-restricted K562 and Daudi tumour cell lines. The
cytotoxic activity of cultured TILs was similar to that detected in
autologous PBTs cultured under the same conditions. Only 4 of 11
TIL cultures were able to lyse autologous tumour cell targets and
in all these cases the TIL cultures displayed higher levels ofcyto-
toxicity against K562 and Daudi targets, suggesting that tumour
cell lysis was mediated by antigen-independent LAK cell-depen-
dent mechanisms. Furthermore, lysis of autologous targets was
enhanced ratherthan inhibited by preincubation oftarget cells with
MHC class I blocking antibodies, which argues against a role for
antigen-restricted cytolytic Tcells. The increased cytolytic activity
observed after MHC class I blockade is likely to reflect NK/LAK
cell activity. Recent evidence suggests that NK cells express
receptors that can recognize polymorphic MHC class I molecules,
and ligation of these so-called killer cell inhibitory receptors by
MHC class I molecules delivers an inhibitory signal to the NK cell
and prevents killing of target cells (Burno et al, 1996; Lanier and
Phillips, 1996).
It is likely that tumour-related factors explain why most TIL
cultures could not lyse autologous tumour cells. Co-stimulatory
signals are crucial for the successful generation and activation
of effector T cells and, in their absence, engagement of the
TCR-CD3 by peptide-MHC complexes results in ineffective T-
cell activation and, in some circumstances, the development of
anergy (Schwartz, 1992; Boussiotis et al, 1994; Chambers and
Allison, 1997). We have shown that tumour cells in colorectal
hepatic metastasis do not express the co-stimulatory molecules
CD80 (B-7.1) or CD86 (B-7.2), which activate T cells through
CD28 to provide co-stimulation for TCR-CD3-mediated activa-
tion. The CD28/B-7 interaction provides a vital co-stimulatory
signal for the generation of an effective anti-tumour T-cell
response and transfection of B-7 into K1735 melanoma cells
increases the immunogenicity of the tumour, resulting in subse-
quent rejection of B-7-negative tumour cells (Townsend and
Allison, 1993; Townsend et al, 1994). Furthermore, tumourcells in
colorectal hepatic metastases express low levels of MHC I (data
not shown), which will hinder their recognition by cytotoxic
T cells, and fail to express MHC II antigens, which will reduce
their ability to efficiently present antigens to CD4+ T cells. On the
other hand, we have shown that T cells infiltrating colorectal
hepatic metastases express CD28, LFA-1 and VLA-4, implying
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that they have the potential to receive co-stimulation via these
pathways if expression of the appropriate ligand could be induced
on tumour cells. Studies of experimental animal models have
shown that ICAM-I expression by tumour cells increases tumour
susceptibility to lysis by effector cells and reduces in vivo tumori-
genicity and that ICAM- I transfection of tumour cells promotes
tumour rejection by T cells (Bumo et al, 1995; Cavallo et al,
1995). In the absence of critical co-stimulatory interactions, it is
not surprising that tumour cells from colorectal hepatic metastasis
are not capable of inducing an effective T-cell response from
cultured TILs, even though the effector lytic mechanism is intact.
Several pieces of evidence from the present study suggest that
colorectal hepatic metastases do not elicit an antigen-specific
T-cell response and, therefore, are not ideal tumours for
immunotherapy. Firstly, although we have shown that culturing
TILs in high-dose IL-2 results in anti-tumour activity, this is
predominantly LAK cell mediated and is transient. It is therefore
unlikely that cultured TILs will be therapeutically effective by the
time sufficient numbers could be generated for reinfusion into the
patient, as Rosenberg's group has shown that the therapeutic effi-
cacy of infused TILs correlates with in vitro autologous tumour
cytotoxicity (Rosenberg et al, 1994). Secondly, colorectal hepatic
metastases are less heavily infiltrated by T cells (the majority of
which are found at the periphery of the tumour rather than in the
parenchyma) compared with tumours such as melanoma and
hepatocellular carcinoma. This suggests that even if it was
possible to provide a high local concentration of cytokines, either
by regional cytokine infusion or by transfecting cytokine genes
into the tumour, the lack ofT cells directly associated with tumour
cells would reduce the chances of a significant enhancement of
anti-tumour responses. Thirdly, even if T cells could be recruited
to colorectal hepatic metastases, it is unlikely that the tumour cells
would elicit an effective anti-tumour CTL response in vivo
because of their low expression of MHC antigens and lack of co-
stimulatory and adhesion molecules. Furthermore, O'Connell's
recent work suggests that lymphocytes infiltrating colorectal
tumours can be induced to undergo apoptosis by interactions with
cancer cells expressing Fas ligand; thus, even if lymphocytes
could be recruited in large numbers to the tumour, they would be
removed before they could mount an effective anti-tumour
response (O'Connell et al, 1996).
In summary, we have shown that the reduced CD3-t expression
in T cells infiltrating colorectal hepatic metastasis is associated
with incomplete cellular activation (CD69 and HLA-Drlig', but
CD251ow, CD71ow), low proliferative activity and impaired
cytolytic effector function. Although both the functional defects
and CD3-1 expression could be restored in vitro by treatment with
high-dose IL-2, tumour-specific CTL activity was not detected in
any of the TIL cultures. This may be because the tumour cells are
poorly immunogenic because of a lack of MHC antigens and co-
stimulatory molecules. We suggest that future strategies for
immunotherapy ofmetastatic colorectal cancer should be aimed at
increasing tumour immunogenicity as well as delivering effector
cells to the tumour.
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